rooperol: structure given in first source; the deglucosidated product of P2A (hypoxoside); RN given for (E)-isomer; RN for cpd without isomeric designation not available 3/93 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6438989 |
| MeSH ID | M0213189 |
| Synonym |
|---|
| rooperol |
| 4-[(e)-5-(3,4-dihydroxyphenyl)pent-1-en-4-ynyl]benzene-1,2-diol |
| 1,2-benzenediol, 4,4'-(1-penten-4-yne-1,5-diyl)bis-, (e)- |
| 1,5-bis(3',4'-dihydroxyphenyl)pent-4-en-1-yne |
| 83644-00-2 |
| p2-bdhpp |
| ([e]-1,5-bis[3',4'-dihydroxyphenyl]pent-4-en-1-yne) |
| (e)-4,4'-(pent-1-en-4-yne-1,5-diyl)bis(benzene-1,2-diol) |
| DTXSID101318740 |
| AKOS040747420 |
Rooperol is a norlignan derivative with numerous biological activities including immunomodulatory, antitumor, anticonvulsant, antibacterial, and antioxidant activities.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rooperol is a norlignan derivative with numerous biological activities including immunomodulatory, antitumor, anticonvulsant, antibacterial, and antioxidant activities. " | ( Antioxidant activity of rooperol investigated through Cu (I and II) chelation ability and the hydrogen transfer mechanism: a DFT study. Kabanda, MM, 2012) | 2.13 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rooperol treatment triggered cell death on NT2/D1 cells through the alteration of mitochondrial membrane potential and production of reactive oxygen species (ROS)." | ( Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells. Ali Azouaou, S; Emhemmed, F; Fuhrmann, G; Idris-Khodja, N; Lobstein, A; Muller, CD; Schini-Kerth, V, 2015) | 1.36 |
This study concerns the pharmacokinetic behaviour and cardiovascular effects of rapid infusions of hypoxoside (CAS 83643-94-1) and rooperol in anaesthetised Chacma baboons.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic studies on mice dosed intragastrically with hypoxoside showed that it was deconjugated by bacterial beta-glucosidase to form rooperol in the colon." | ( Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. Albrecht, CF; Kruger, PB; Theron, EJ, 1995) | 0.72 |
| "This study concerns the pharmacokinetic behaviour and cardiovascular effects of rapid infusions of hypoxoside (CAS 83643-94-1) and rooperol (CAS 83644-00-2) in anaesthetised Chacma baboons." | ( Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol. Albrecht, CF; Coetzee, JF; Jahed, N; Kruger, PB; van Jaarsveld, PP, 1996) | 0.72 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic studies on mice dosed intragastrically with hypoxoside showed that it was deconjugated by bacterial beta-glucosidase to form rooperol in the colon." | ( Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. Albrecht, CF; Kruger, PB; Theron, EJ, 1995) | 0.72 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||